ISSUE: May 1, 2013 - American Lifestyle is announcing that it is conducting a voluntary recall of all lots of Vicerex UPC 893490820087 and Black Ant UPC 4026666142546. Laboratory analysis conducted by the FDA has determined the Vicerex product contains undeclared tadalafil and the Black Ant product contains undeclared sildenafil. Tadalafil and sildenafil are FDA-Approved drugs used to treat male erectile dysfunction (ED), making the Vicerex and the Black Ant products unapproved new drugs.
These undeclared active ingredients poses a threat to consumers because tadalafil and sildenafil may interact with nitrates found in some prescription drugs such as nitroglycerin and may lower blood pressure to dangerous levels. Consumers with diabetes, high blood pressure, high cholesterol, or heart disease often take nitrates. No Adverse events have been reported related to this recall.
BACKGROUND: Vicerex is sold in blister packs containing ten (10) capsules and Black Ant is sold in a box containing four (4) individually wrapped capsules. The product is distributed worldwide by American Lifestyle by on-line sales and retail. The products are being promoted for increasing desire and sexual performance. The products are sold without medical prescription.
RECCOMENDATION: American Lifestyle is notifying its customers by telephone and email and is arranging for return of all recalled products. Consumers who have purchased Vicerex or Black Ant capsules are urged to immediately discontinue their use and return the product to their place of purchase or directly to American Lifestyle, 640 Kreag Road, Pittsford, NY 14534. Consumers are asked to have order number or proof of purchase.
Consumers with questions regarding this recall may contact American Lifestyle at 585-586-1878 Monday through Friday 7 am to 3 pm EST.
Consumers who have purchased any of these products and have any of the mentioned medical illnesses should consult their health care providers.
Adverse reaction or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program online, by regular mail, or by fax.
[05/01/2013 - Press Release - American Lifestyle]
[03/16/2011 - Public Notification - FDA]
Previous MedWatch Alert:
[03/16/2011 - MedWatch Alert - FDA]